ARTICLE | Company News

Casebia, Seattle Children's partner to develop gene-edited Tregs

September 27, 2017 10:00 PM UTC

Casebia Therapeutics (Cambridge, Mass.) and Seattle Children's Research Institute (Seattle, Wash.) partnered to develop CRISPR-Cas9 (CRISPR-associated protein 9)-edited Tregs to treat and prevent autoimmune diseases.

The partners will build on technologies developed in the labs of David Rawlings and Andrew Scharenberg at Seattle Children's for selectively editing, manufacturing and expanding a patient's own T cells. In July, Scharenberg joined Casebia as CSO and VP of hematology...